Shares of Moderna fell 4.68% to $137.26 at 09:51 EST on Friday, after three successive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.84% to $12,764.80, after four sequential sessions in a row of gains. This seems, at the moment, a somewhat positive trend trading session today.
Moderna's last close was $137.03, 30.05% below its 52-week high of $178.50.
News about Moderna today
Moderna shot expected to bolster U.S. vaccine efforts. According to today's article on The Wall Street Journal, "If authorized, Moderna's vaccine will join a vaccine from Pfizer Inc. and BioNTech SE that received authorization on Dec. 11.", ""The addition of the Moderna vaccine to the response will be huge," said Claire Hannan, executive director of the Association of Immunization Managers, whose members direct state vaccination efforts. "
Moderna authorization bid to get quick FDA attention, hahn says. According to today's article on Bloomberg Quint, "Between Pfizer and Moderna, up to 20 million people in the U.S. are expected to get their first shots by year-end.", "The U.S. Food and Drug Administration will work quickly toward authorizing Moderna Inc.'s Covid-19 vaccine that agency advisers voted Thursday to recommend, Commissioner Stephen Hahn said."
FDA speeds toward Moderna vaccine authorization as soon as today. According to today's article on Bloomberg Quint, "The FDA told Moderna "that it will rapidly work toward finalization and issuance of an emergency use authorization," Hahn said late Thursday in a statement. ", "Moderna's vaccine is expected to play an important role in the government's plans for mass immunization and slowing the pandemic. "
Moderna's Sales
Moderna's sales growth is 1665.3% for the ongoing quarter and 15587.1% for the next. The company's growth estimates for the current quarter is a negative 29.7% and positive 685.7% for the next.
Moderna's Revenue
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna's Stock Yearly Top and Bottom Value
Moderna's stock is valued at $137.26 at 09:51 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.68.
Moderna's Moving Average
Moderna's value is way above its 50-day moving average of $110.24 and way higher than its 200-day moving average of $79.01.Previous days news about Moderna
Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to The Wall Street Journal on Tue Dec 15, "-Shares of the vaccine maker Moderna were down 1% premarket. "
Moderna vaccine found safe, effective ahead of key FDA review. According to Bloomberg Quint on Tue Dec 15, "Moderna's vaccine will be distributed to sites around the country where health-care workers and residents of long-term care facilities, such as nursing homes, are expected to get the earliest doses.", "Moderna's vaccine isn't yet approved in any other countries and hasn't yet been used on anyone outside of a clinical trial."
Moderna vaccine found safe, effective before key FDA review. According to Bloomberg Quint on Tue Dec 15, "The FDA got a much deeper look at Moderna's clinical-trial data than the numbers previously released to the public by the company. ", "Between Pfizer and Moderna, Operation Warp Speed officials have said 20 million people in the U.S. are expected to get their first shots by year-end."
Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to MarketWatch on Tue Dec 15, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. "
Canada to receive early access to Moderna Covid-19 vaccine. According to Business Insider on Tue Dec 15, "The Moderna vaccine would be the first delivered through the end-to-end COVID-19 logistics services contract awarded to FedEx Express Canada and Innomar Strategies Inc.", "Today, the Honourable Anita Anand, Minister of Public Services and Procurement, announced that following successful negotiations and contingent on Health Canada authorization of the vaccine, Canada will be able to access 168,000 doses of the Moderna COVID-19 vaccine in December 2020."
Moderna to offer covid shots to volunteers who got placebo. According to Bloomberg Quint on Tue Dec 15, "Moderna Inc. is preparing to offer its Covid-19 shot to trial participants who received a placebo in the final-stage study once the vaccine is authorized for emergency use in the U.S.", "Ray Jordan, a Moderna spokesman, confirmed the letter was being prepared."
Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Moderna (MRNA) - Moderna was downgraded to "hold" from "buy" at Jefferies, which cited the significant runup in the drugmaker's stock as well as high expectations surrounding its Covid-19 vaccine. "
Moderna party ending, analysts caution before shot approval. According to Bloomberg Quint on Wed Dec 16, "Moderna Inc's swift rise -- much of it driven by daytraders speculating over the chances of its Covid-19 vaccine getting approval -- is picking up more detractors on Wall Street by the day.", "Moderna's valuation may be at risk if retail interest wanes as new vaccines become a reality. "
FDA panel expected to back Moderna Covid-19 vaccine. According to The Wall Street Journal on Thu Dec 17, "A federal vaccine-advisory committee is likely to recommend that the Food and Drug Administration grant an emergency-use authorization for the new Covid-19 vaccine from Moderna Inc. when the panel meets Thursday, its chairman said."
Global market outlook for the coronavirus vaccine market to 2027, featuring Moderna inc, geovax, inovio pharmaceuticals and more. According to Business Insider on Thu Dec 17, "Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.", "Key Topics Covered:1 Executive Summary 2 Preface3 Market Trend Analysis4 Porters Five Force Analysis5 Global Coronavirus Vaccine Market, By Infection Type6 Global Coronavirus Vaccine Market, By Vaccine Type7 Global Coronavirus Vaccine Market, By Product Type8 Global Coronavirus Vaccine Market, By Route of Administration9 Global Coronavirus Vaccine Market, By Patient Type10 Global Coronavirus Vaccine Market, By End User11 Global Coronavirus Vaccine Market, By Geography12 Key Developments13 Company Profiling13.1 Inovio Pharmaceuticals, Inc. 13.2 Moderna, Inc. 13.3 Protein Potential, LLC 13.4 Novavax, Inc. 13.5 Synairgen PLC 13.6 AlphaVax, Inc. 13.7 NanoViricides, Inc. 13.8 Zydus Cadila 13.9 Bravovax 13.10 GeoVax 13.11 Altimmune 13.12 Janssen Pharmaceutical Companies 13.13 CanSino Biologics 13.14 Vaxart 13.15 Vaxil Bio Ltd For more information about this report visit https://www.researchandmarkets.com/r/5b6t0s"
FDA advisory panel endorses use of Moderna Covid-19 vaccine. According to MarketWatch on Thu Dec 17, "An independent advisory committee on Thursday voted 20-0-1 that the benefits of Moderna Inc.'s COVID-19 vaccine candidate outweigh the risks, a recommendation that sets the stage for the likely second FDA authorization of a vaccine during the pandemic.", "Shares of Moderna gained 1.2% in after-hours trading on Thursday after the vote."
Moderna ditches 400,000 vaccine doses but still set to meet goal. According to Bloomberg Quint on Thu Dec 17, "Such challenges are to be expected when pursuing a complex manufacturing process like that needed for Moderna's messenger RNA vaccine, according to Slaoui. ", "Moderna, however, remains on track to meet its production estimates of 20 million doses this month, and 85 to 100 million doses for the U.S. in the first quarter of 2021, according to Ray Jordan, a spokesman for the Cambridge, Massachusetts-based company."
Experts back Moderna vaccine; n.y. toll above 100: virus update. According to Bloomberg Quint on Thu Dec 17, "Moderna's product is based on the same technology as a shot made by Pfizer Inc. and BioNTech SE that was cleared by the FDA last week, and like that vaccine showed a high degree of efficacy in late-stage clinical trials. ", "The Evergreen State, which has about 7.6 million residents, would also get 183,800 doses of Moderna's vaccine this month if that inoculation is approved by regulators. "